Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof
A vaccine comprising an immunologically effective amount of recombinant modified vaccinia Ankara (rMVA) virus which is genetically stable after serial passage and produced by a) constructing a transfer plasmid vector comprising a modified H5 (mH5) promoter operably linked to a DNA sequence encoding a heterologous foreign protein antigen, wherein the expression of said DNA sequence is under the control of the mH5 promoter; b) generating rMVA virus by transfecting one or more plasmid vectors obtained from step a) into wild type MVA virus; c) identifying rMVA virus expressing one or more heterologous foreign protein antigens using one or more selection methods for serial passage; d) conducting serial passage; e) expanding an rMVA virus strain identified by step d); and f) purifying the rMVA viruses from step e) to form the vaccine. One embodiment is directed to a fusion cytomegalovirus (CMV) protein antigen comprising a nucleotide sequence encoding two or more antigenic portions of Immediate-Early Gene-1 or Immediate-Early Gene-2 (IEfusion), wherein the antigenic portions elicit an immune response when expressed by a vaccine.
1. A fusion nucleotide sequence which encodes an IEfusion cytomegalovirus (CMV) protein antigen, said fusion nucleotide sequence comprising a nucleotide sequence encoding an-Immediate-Early Gene-1 (IE1) antigenic portion directly fused to a nucleotide sequence encoding an Immediate-Early Gene-2 (IE2) antigenic portion,
wherein the nucleotide sequence encoding the IE1 antigenic portion includes a nucleotide sequence encoding IE1 exon 4 (IE1/e4).
2. The fusion nucleotide sequence of claim 1 , wherein the fusion nucleotide sequence is SEQ ID NO:11.
3. The fusion nucleotide sequence of claim 1 , wherein the nucleotide sequence encoding the IE2 antigenic portion is a nucleotide sequence encoding IE2 exon 5 (IE2/e5).
4. The fusion nucleotide sequence of claim 1 , wherein the fusion nucleotide sequence is operably linked to a modified H5 (mH5) promoter.
5. A fusion nucleotide sequence which encodes an IEfusion cytomegalovirus (CMV) protein antigen, said fusion nucleotide sequence comprising a nucleotide sequence encoding an-Immediate-Early Gene-1 (IE1) antigenic portion directly fused to a nucleotide sequence encoding an Immediate-Early Gene-2 (IE2) antigenic portion,
wherein the nucleotide sequence encoding the IE2 antigenic portion is a nucleotide sequence encoding IE2 exon 5 (IE2/e5).
6. The fusion nucleotide sequence of claim 5 , wherein the fusion nucleotide sequence is operably linked to a modified H5 (mH5) promoter.
7. An rMVA virus comprising a fusion nucleotide sequence which encodes an IEfusion cytomegalovirus (CMV) protein antigen, said fusion nucleotide sequence comprising a nucleotide sequence encoding an-Immediate-Early Gene-1 (IE1) antigenic portion directly fused to a nucleotide sequence encoding an Immediate-Early Gene-2 (IE2) antigenic portion, wherein
(i) the nucleotide sequence encoding the IE1 antigenic portion includes a nucleotide sequence encoding IE1 exon 4 (IE1/e4);
(ii) the nucleotide sequence encoding the IE2 antigenic portion is a nucleotide sequence encoding IE2 exon 5 (IE2/e5); or
(iii) both (i) and (ii).
8. The rMVA virus of claim 7 , wherein the fusion nucleotide sequence comprises SEQ ID NO:11.
9. The rMVA virus of claim 7 , further comprising a nucleotide sequence which encodes HCMV-pp 65.
10. A method of eliciting an immune response against CMV in a human subject, comprising administering the rMVA virus of claim 7 to the subject.